Arena Pharmaceuticals Inc
F:RN3N
Balance Sheet
Balance Sheet Decomposition
Arena Pharmaceuticals Inc
Arena Pharmaceuticals Inc
Balance Sheet
Arena Pharmaceuticals Inc
| Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
156
|
222
|
163
|
156
|
91
|
159
|
161
|
243
|
220
|
225
|
|
| Cash Equivalents |
156
|
222
|
163
|
156
|
91
|
159
|
161
|
243
|
220
|
225
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
88
|
285
|
496
|
885
|
326
|
|
| Total Receivables |
6
|
11
|
4
|
5
|
20
|
14
|
5
|
2
|
0
|
0
|
|
| Accounts Receivables |
6
|
11
|
4
|
5
|
20
|
2
|
5
|
2
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
12
|
0
|
0
|
0
|
0
|
|
| Inventory |
6
|
13
|
11
|
10
|
7
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
4
|
4
|
4
|
4
|
2
|
20
|
10
|
19
|
35
|
19
|
|
| Total Current Assets |
171
|
249
|
182
|
175
|
120
|
281
|
461
|
760
|
1 139
|
569
|
|
| PP&E Net |
75
|
77
|
83
|
72
|
44
|
30
|
23
|
37
|
33
|
28
|
|
| PP&E Gross |
75
|
77
|
83
|
72
|
44
|
30
|
23
|
37
|
33
|
28
|
|
| Accumulated Depreciation |
84
|
88
|
92
|
101
|
65
|
58
|
46
|
49
|
53
|
56
|
|
| Intangible Assets |
11
|
10
|
9
|
8
|
2
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
24
|
82
|
371
|
0
|
161
|
|
| Other Long-Term Assets |
4
|
3
|
3
|
2
|
3
|
4
|
121
|
6
|
19
|
26
|
|
| Total Assets |
261
N/A
|
340
+30%
|
276
-19%
|
257
-7%
|
169
-34%
|
339
+101%
|
687
+102%
|
1 174
+71%
|
1 191
+1%
|
785
-34%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
4
|
4
|
3
|
2
|
6
|
2
|
6
|
6
|
12
|
13
|
|
| Accrued Liabilities |
6
|
8
|
14
|
11
|
10
|
38
|
20
|
35
|
42
|
48
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
2
|
2
|
3
|
3
|
4
|
4
|
3
|
4
|
4
|
5
|
|
| Other Current Liabilities |
18
|
57
|
48
|
34
|
44
|
29
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
30
|
71
|
67
|
50
|
64
|
72
|
30
|
45
|
58
|
66
|
|
| Long-Term Debt |
73
|
71
|
68
|
65
|
62
|
58
|
49
|
46
|
41
|
36
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
60
|
107
|
93
|
88
|
3
|
2
|
1
|
12
|
11
|
9
|
|
| Total Liabilities |
163
N/A
|
248
+53%
|
229
-8%
|
203
-11%
|
129
-36%
|
132
+2%
|
81
-39%
|
103
+27%
|
110
+7%
|
111
+1%
|
|
| Equity | |||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
1 188
|
1 208
|
1 268
|
1 376
|
1 399
|
1 490
|
1 501
|
1 103
|
1 508
|
2 124
|
|
| Additional Paid In Capital |
1 281
|
1 294
|
1 313
|
1 431
|
1 442
|
1 699
|
2 107
|
2 173
|
2 588
|
2 798
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
6
|
6
|
3
|
1
|
3
|
1
|
0
|
1
|
1
|
0
|
|
| Total Equity |
99
N/A
|
92
-7%
|
47
-49%
|
54
+13%
|
40
-25%
|
207
+419%
|
606
+193%
|
1 072
+77%
|
1 081
+1%
|
673
-38%
|
|
| Total Liabilities & Equity |
261
N/A
|
340
+30%
|
276
-19%
|
257
-7%
|
169
-34%
|
339
+101%
|
687
+102%
|
1 174
+71%
|
1 191
+1%
|
785
-34%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
22
|
22
|
22
|
24
|
24
|
39
|
49
|
50
|
59
|
62
|
|